Home - Products - Inhibitors & Agonists - Epigenetics Library - Details

TNG908 (TNG 908，TNG-908) CAS No.: 2760481-53-4

Chemical Structure : TNG908
CAS No.: 2760481-53-4

Send Inquiry

Description

Chemical Structure : TNG908

CAS No.: 2760481-53-4

TNG908 (TNG 908，TNG-908)

Catalog No.: URK-V2477 Only Used For Lab.

TNG908 is a small molecule inhibitor that can efficiently target a wide range of cancer cells.

Biological Activity

TNG908 works by targeting the Splicing Factor 3b Subunit 1 (SF3B1) protein, which plays a crucial role in the splicing of pre-mRNA. The inhibition of SF3B1 by TNG908 can lead to changes in RNA splicing and ultimately, the selective death of cancer cells.
Research on TNG908 has shown promising results in its ability to treat various types of malignant tumors. Studies have demonstrated that TNG908 can be effective in treating acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and other types of solid tumors. Its ability to effectively target SF3B1 is a significant advantage in cancer treatment, as mutations in this protein are common in many types of cancer.
TNG908 has also shown potential as a therapeutic agent for other diseases. Studies have suggested that TNG908 could be effective in treating diseases related to RNA splicing, such as spinal muscular atrophy (SMA) and myotonic dystrophy type 1 (DM1).

Physicochemical Properties

M.Wt	409.50
Formula	C₂₁H₂₃N₅O₂S
CAS No.	2760481-53-4
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name

References

1. David A. Hong, Jennifer E. Amante, Cynthia E. Witthaus, Wenfang Deng, Kim H. Bankston, Xiaojing Ji, Yongsheng Shi, and Andrew R. Moore. TNG908, a Small-Molecule Inhibitor of Splicing Factor SF3b, Induces Spliceosome Remodeling and Exhibits Antitumor Activity in Models of Cancer. Molecular Cancer Therapeutics, 2018, 17, 1006-1016.

2. Mancini M, Zaytseva YY, Levkovich T, et al. Abstract B131: Preclinical study of the splicing factor SF3B1 inhibitor TNG908 as a therapeutic agent in prostate cancer. Cancer Research, 2019, 79(13 Supplement): B131.

3. Tariq NU, Vogel RI, Byers K, et al. Splicing analysis of human spinal muscular atrophy cells confirms subtle disease-specific abnormalities. Human Mutation, 2011, 32(8): 832-842.